Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys-Reference-Cited by-同舟云学术

Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

Published:2000-04 Issue:2 Volume:162 Page:321-327
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Kanda Tomoyuki,Jackson Michael J.,Smith Lance A.,Pearce Ronald K.B.,Nakamura Joji,Kase Hiroshi,Kuwana Yoshihisa,Jenner Peter

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference34 articles.

1. Overview of morphological changes in Parkinson's disease;Jellinger;Adv. Neurol.,1987

2. Biochemical pathophysiology of Parkinson's disease;Hornykiewicz;Adv. Neurol.,1987

3. Practical therapy of Parkinson's disease;Kurlan;Semin. Neurol.,1987

4. Pathogenesis of dyskinesias in Parkinson's disease;Mouradian;Ann. Neurol.,1989

5. COMT inhibition: A new treatment strategy for Parkinson's disease;Kurth;Neurology,1998

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets;Journal of Pharmacological Sciences;2023-07

2. Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia;Neuropharmacology;2023-03

3. How and why the adenosine A2A receptor became a target for Parkinson’s disease therapy;International Review of Neurobiology;2023

4. Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential;Topics in Medicinal Chemistry;2023

5. Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios;Degenerative Neurological and Neuromuscular Disease;2022-07